Status:
COMPLETED
Risk Factors for the Leakage of Anticancer Drugs to Systemic Circulation by Transcatheter Arterial Chemoembolization
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
20-80 years
Brief Summary
Hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver. Transcatheter arterial chemoembolization (TACE) is the traditional method for the palliative management of patients with...
Eligibility Criteria
Inclusion
- Patients with hepatocellular carcinoma caused by hepatitis B or C who will be treated by TACE
Exclusion
- Previously treated by antiviral drugs for hepatitis B or C
Key Trial Info
Start Date :
February 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT00630240
Start Date
February 1 2008
End Date
February 1 2009
Last Update
September 1 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Hepatobiliary Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, No. 100 Tzyou 1st Road
Kaohsiung City, Taiwan, 807